Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Denali Therapeutics Inc (NQ: DNLI)
20.02 USD  -0.61 (-2.96%)
Official Closing Price  /  Updated: 5:46 PM EDT, Jul 16, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 315,500
Open 20.53
Bid (Size) 19.50 (1)
Ask (Size) 22.50 (3)
Prev. Close 20.63
Today's Range 19.86 - 20.56
52wk Range 12.32 - 28.86
Shares Outstanding 94,441,892
Dividend Yield N/A
Performance
YTD
+3.57%
+3.57%
1 Month
+2.40%
+2.40%
3 Month
-25.24%
-25.24%
6 Month
-4.67%
-4.67%
1 Year
+42.49%
+42.49%
Top News
More News
Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that the FDA granted Orphan Drug... Read More
from GlobeNewswire News Releases
Growth at Flagship Pioneering Leads to New Executive Appointments
Expertise Added to Support Growth of Transformative Companies Originated by Flagship Labs Read More
from PR Newswire
More News
Read More
Denali Therapeutics Reports First Quarter 2019 Financial Results
from GlobeNewswire News Releases
Flagship Pioneering Unveils Kintai Therapeutics and Appoints Pharmaceutical Drug Developer Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer
from PR Newswire
First Week of August 16th Options Trading For Denali Therapeutics (DNLI)
category Stocks
from Market News Video
DNLI Crosses Above Key Moving Average Level
category Stocks
from Market News Video
Notable Two Hundred Day Moving Average Cross - DNLI
category Stocks
from Market News Video
Analysts Forecast 16% Upside For VBR
category ETFs
from ETF Channel
DNLI Crosses Above Average Analyst Target
category ETFs
from ETF Channel
The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
category Offerings , Earnings , FDA , and 22 more.
from Benzinga
3 Biotech Stocks That Doubled After Hitting Bottom in 2018
category ACAD , SNY , DNLI , and 2 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
© Copyright FinancialContent Services, Inc.